Idarubicin HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100450

CAS#: 57852-57-0(HCl)

Description: Idarubicin is a semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.


Price and Availability

Size
Price

10mg
Not available
100mg
Not available
1g
USD 4250
Size
Price

25mg
Not available
200mg
USD 2150
2g
USD 6750
Size
Price

50mg
Not available
500mg
USD 3250
5g
Ask price

Idarubicin HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100450
Name: Idarubicin HCl
CAS#: 57852-57-0(HCl)
Chemical Formula: C26H28ClNO9
Exact Mass:
Molecular Weight: 533.958
Elemental Analysis: C, 58.49; H, 5.29; Cl, 6.64; N, 2.62; O, 26.97


Synonym: IMI30; IMI-30; IMI 30; NSC256439; NSC-256439; NSC 256439; 4-DMDR; IDA; 4-Demethoxydaunomycin; brand name: Idamycin; IDAMYCIN PFS.

IUPAC/Chemical Name: (7S,9S)-9-acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride

InChi Key: JVHPTYWUBOQMBP-RVFAQHLVSA-N

InChi Code: InChI=1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10-,15-,16-,17-,21+,26-;/m0./s1

SMILES Code: O=C1C2=C(O)C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@](O)(C(C)=O)C4)=C4C(O)=C2C(C5=C1C=CC=C5)=O.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
CAS#57852-57-0( Idarubicin HCl)
CAS#58957-92-9 ( Idarubicin free base).


References

1: Vigliotti ML, Dell'Olio M, La Sala A, Romano G, Tartarone A, Mele G, Musto C, Carella AM, Di Renzo N. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy. Hematol J. 2004;5(5):453-5. Review. PubMed PMID: 15448676.

2: Crivellari D, Lombardi D, Spazzapan S, Veronesi A, Toffoli G. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol. 2004 Feb;49(2):153-63. Review. PubMed PMID: 15012975.

3: Leone G, Sica S, Pagano L. Idarubicin including regimens in acute myelogenous leukemia in elderly patients. Crit Rev Oncol Hematol. 1999 Sep;32(1):59-68. Review. PubMed PMID: 10586356.

4: Zinzani PL. Idarubicin in low-grade non-Hodgkin's lymphomas. Haematologica. 1997 Sep-Oct;82(5 Suppl):23-4. Review. PubMed PMID: 9402750.

5: Buckley MM, Lamb HM. Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Drugs Aging. 1997 Jul;11(1):61-86. Review. PubMed PMID: 9237041.

6: Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther. 1997 Feb;35(2):80-3. Review. PubMed PMID: 9147715.

7: Tamura K. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Semin Hematol. 1996 Oct;33(4 Suppl 3):2-11. Review. PubMed PMID: 8916310.

8: Leoni F, Ciolli S, Giuliani G, Pascarella A, Caporale R, Salti F, Cervi L, Rossi Ferrini P. Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Br J Haematol. 1995 May;90(1):169-74. Review. PubMed PMID: 7786781.

9: Gabel C, Eifel PJ, Tornos C, Burke TW. Radiation recall reaction to idarubicin resulting in vaginal necrosis. Gynecol Oncol. 1995 May;57(2):266-9. Review. PubMed PMID: 7729748.

10: Chalmers EA, Franklin IM, Kelsey S, Clarke R, Sproul AM, Goldstone AH, Hepplestone A, Watson W, Sharp S, Tansey P. Mobilisation of Ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine. Bone Marrow Transplant. 1994;14 Suppl 3:S38-41. Review. PubMed PMID: 7697006.